google-site-verification: googlec7193c3de77668c9.html

Recent Posts

Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer

[ Credit: Pixabay/CC0 Public Domain Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference …

Read More »
Available for Amazon Prime